Navigation Links
Amarin Secures Global Intellectual Property Rights for Lipid Programs
Date:3/3/2008

ection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: risks relating to the Company's ability to maintain its Nasdaq listing; Amarin's ability to maintain sufficient cash and other liquid resources to meet its operating and debt service requirements; the success of Amarin's research and development activities; decisions by regulatory authorities regarding whether and when to approve Amarin's drug applications, as well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin's products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affecting Amarin's products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; general changes in International and US generally accepted accounting principles; and growth in costs and expenses. A further list and description of these risks, uncertainties and other matters can be found in Amarin's Form 20-F for the fiscal year ended December 31, 2006, filed with the SEC on March 5, 2007, Amarin's statutory annual report for the year ended 31 December, 2006 furnished on a Form 6-K to the SEC on May 9, 2007, Amarin's Report of Foreign Issuer (Updated and Additional Risk
'/>"/>
SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarin Appoints Dr. William Mason as Lead Independent Director
2. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
3. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
4. Amarin Signs Agreement to Acquire Ester Neurosciences
5. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
6. Amarin Announces Initiation of Cardiovascular Development Strategy
7. Amarin to Present at 4th Annual Bio Investor Forum
8. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
9. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
10. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
11. Taligen Therapeutics Secures Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Rogne Bioscience, a privately-held biotechnology company based ... has acquired a licence to anti-inflammatory peptides from Isis ... anti-inflammatory activity of the peptides was discovered by Professor ... Sir William Dunn School of Pathology. ... million in seed financing, is developing a first-in-class, topical ...
(Date:7/31/2014)... CollabRx, Inc. (NASDAQ: CLRX), a leading ... oncology, today announced that it will hold an investor ... Company's financial results for the first quarter of fiscal ... in the current fiscal year. , The dial-in number ... 14, 2014, at 5 p.m. EDT (2 p.m. PDT) ...
(Date:7/31/2014)... San Diego, CA (PRWEB) July 31, 2014 ... company announced today the integration of Omicsoft’s Array Suite ... to both platforms will be able to send data ... The integration works with all versions of tranSMART including ... of the art statistics, visualization and storage for the ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
Breaking Biology Technology:Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2
... 7, 2011 Cellectis (Alternext: ALCLS), the ... its nuclease production capacity has increased ten-fold ... of the nuclease manufacturing gives Cellectis bioresearch, ... of Cellectis, the potential to supply the ...
... , Inc. ( www.sermo.com ), the largest online physician ... of Sermo Sponsorship, a portfolio of offerings that provides ... to engage physicians and educate them on new products ... and mobile platforms, where physicians across 68 specialties discuss ...
... Sanford Rose Associates® - San Diego, focusing exclusively on assignments ... another successful placement. Mr. John Sperzel has been selected for ... a global provider of Point of Care testing systems and ... Directors. Mr. Sperzel is a dynamic business leader ...
Cached Biology Technology:Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 2Sermo, Inc. Introduces New Sponsorship Product for Pharma, Biotech and Life Sciences 2Sermo, Inc. Introduces New Sponsorship Product for Pharma, Biotech and Life Sciences 3John Sperzel Appointed as Chief Executive Officer of ITC Nexus Dx 2
(Date:7/31/2014)... are the largest minority group in the United States, ... Latinos are obese and are 1.2 times as likely ... NYU College of Nursing student researcher Lauren Gerchow, BSN, ... that contribute to this problem by compiling a systematic ... in Latina women recently published in Nursing Research ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... in spite of waves that sometimes pound the shore ... 600 miles per hour are more prone to snap ... the American Association for the Advancement of Science meeting in ... reported that the fibrous threads she calls "nature,s bungee cords" ...
... or impacted wisdom teeth? As we humans evolved ... brains and shorter jaws, bear big babies and live longer, ... becoming the world,s most successful primate, at nearly 7 billion ... help us better deal with issues from obesity to difficult ...
... the University of Huddersfield aims to ensure that the risk of ... lead plumbing is reduced even further in line with new ... The project is being conducted in collaboration with Yorkshire ... such as European nations and the USA, have similar issues with ...
Cached Biology News:Mussels cramped by environmental factors 2Mussels cramped by environmental factors 3Is there a Neanderthal in the house? 2Research with Yorkshire Water to reduce lead in water supplies 2
Applications: (+) Immunocytochemistry and immunohistochemistry...
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Non-Protein Peroxidase Stabilizer , 1 L...
... Lysate contains the cellular components necessary for ... elongation and termination factors) but has not ... is used primarily for the isolation of ... of endogenous globin mRNA. Untreated Lysate is ...
Biology Products: